

细胞色素p450家族基因多态性与他莫昔芬临床疗效的关系

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年04期 页码: 696-699 栏目: 综述 出版日期: 2019-01-08

Title: Research advances on the relationship between cytochrome p450 family gene polymorphism and tamoxifen clinical efficacy

作者: 许馨元; 蔡莉
哈尔滨医科大学附属肿瘤医院肿瘤内科, 黑龙江 哈尔滨 150081

Author(s): Xu Xinyuan; Cai Li
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Heilongjiang Harbin 150081, China.

关键词: 他莫昔芬; 细胞色素p450; 基因多态性

Keywords: tamoxifen; cytochrome p450; gene polymorphism

分类号: R737.9

DOI: 10.3969/j.issn.1672-4992.2019.04.040

文献标识码: A

摘要: 目前, 他莫昔芬广泛用于雌激素受体阳性的乳腺癌患者, 可大幅度降低患者的复发和死亡, 已成为抗雌激素治疗的标准用药。p450酶系是他莫昔芬代谢的关键酶, 从而影响他莫昔芬的治疗效果。临床上对他莫昔芬治疗的个体反应性存在高度差异, 可能与p450家族基因多态性有着密切联系。本文主要对CYP2D6、CYP3A4/5、CYP2C19基因的多态性与他莫昔芬的代谢及疗效之间的关系进行简要阐述。

Abstract: Tamoxifen is widely used in breast cancer patients with positive estrogen-receptor, it can significantly reduce the recurrence and mortality of the patients, and becomes the standard drug for anti-estrogen. The p450 enzyme is a key enzyme in tamoxifen metabolism, which affects its therapeutic effect. However, there was a high degree of variation in the reaction between individuals to tamoxifen, which was closely related to the gene polymorphism of the p450 family. In this paper, the relationship between the polymorphism of CYP2D6, CYP3A4/5, CYP2C19 gene and the metabolism and efficacy of tamoxifen was briefly described.

参考文献/REFERENCES

- [1] Ziaei S. Dietary isoflavones and breast cancer risk [J]. *Medicines (Basel, Switzerland)*, 2017, 4(2):301-311.
- [2] Leung EY, Askarian-Amiri ME, Sarkar D, et al. Endocrine therapy of estrogen receptor-positive breast cancer cells: Early differential effects on stem cell markers [J]. *Frontiers in Oncology*, 2017, 7:184.
- [3] De Vries Schultink AH, Zwart W, Linn SC, et al. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen [J]. *Clinical Pharmacokinetics*, 2015, 54(8):797-810.
- [4] Damkier P, Kjaersgaard A, Barker KA, et al. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the international tamoxifen pharmacogenomics consortium dataset [J]. *Scientific Reports*, 2017, 7(1):7727.
- [5] Ter Heine R, Binkhorst L, de Graan AJ, et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen [J]. *British Journal of Clinical Pharmacology*, 2014, 78(3):572-586.
- [6] Antunes MV, de Oliveira V, Raymundo S, et al. CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen [J]. *Pharmacogenomics*, 2015, 16(6):601-617.
- [7] Sanchez Spitman AB, Moes DJAR, Gelderblom H, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism [J]. *European Journal of Clinical Pharmacology*, 2017, 73(12):1589-1598.
- [8] Teft WA, Gong IY, Dingle B, et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy [J]. *Breast Cancer Research and Treatment*, 2013, 139(1):95-105.
- [9] Charoenchokthavee W, Areepium N, Panomvana D. Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients [J]. *Breast Cancer (Dove Medical Press)*, 2017, 9:249-256.
- [10] Zhang YX, Li YF, Chen B, et al. Correlation between polymorphisms of CYP3A5 and CYP2D6 genotypes with concentrations of Tamoxifen and its activity metabolism 4-hydroxytamoxifen in Chinese breast cancer patients [J]. *China Pharmacist*, 2010, 13(09):1229-1232. [张宇馨, 李亚芬, 陈冰, 等. 中国CYP3A5和CYP2D6基因多态性与他莫昔芬及其活性代谢物浓度的相关性 [J]. *中国药师*, 2010, 13(09):1229-1232.]

- [11] Goetz MP,Rae JM,Suman VJ,et al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes [J] .Journal of Clinical Oncology,2005,23(36):9312-9318.
- [12] Schroth W,Antoniadou L,Fritz P,et al.Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes [J] .Journal of Clinical Oncology,2007,25(33):5187-5193.
- [13] Sensorn I,Sirachainan E,Chamnanphon M,et al.Association of CYP3A4/5,ABCB1 and ABC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen [J] .Pharmacogenomics and Personalized Medicine,2013,6:93-98.
- [14] Wegman P,Elingarami S,Carstensen J,et al.Genetic variants of CYP3A5,CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer [J] .Breast Cancer Research,2007,9(1):R7.
- [15] Lim JS,Chen XA,Singh O,et al.Impact of CYP2D6,CYP3A5,CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients [J] .British Journal of Clinical Pharmacology,2011,71(5):737-750.
- [16] Powers JL,Buys SS,Fletcher D,et al.Multigene and drug interaction approach for tamoxifen metabolite patterns reveals possible involvement of CYP2C9,CYP2C19,and ABCB1 [J] .Journal of Clinical Pharmacology,2016,56(12):1570-1581.
- [17] Saladores P,Mürdter T,Eccles D,et al.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer [J] .The Pharmacogenomics Journal,2015,15(1):84-94.
- [18] van Schaik RH,Kok M,Sweep FC,et al.The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients [J] .Pharmacogenomics,2011,12(8):1137-1146.
- [19] Beelen K,Opdam M,Severson TM,et al.CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment [J] .Breast Cancer Research and Treatment,2013,139(3):649-655.
- [20] Mwinyi J,Vokinger K,Jetter A,et al.Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy [J] .Cancer Chemotherapy and Pharmacology,2014,73(6):1181-1188.
- [21] Goetz MP.CYP2D6 genotype and tamoxifen:considerations for proper nonprospective studies [J] .Clinical Pharmacology and Therapeutics,2014,96(2):141-144.
- [22] Pesenti C,Gusella M,Sirchia SM.Germline oncoparmacogenetics, a promising field in cancer therapy [J] .Cellular Oncology (Dordrecht),2015,38(1):65-89.
- [23] Blackburn HL,Ellsworth DL,Shriver CD.Role of cytochrome p450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis,metabolism,and response to endocrine therapy [J] .Cancer Causes & Control,2015,26(3):319-332.
- [24] Markopoulos C,Kykalos S.Impact of CYP2D6*6 in the adjuvant treatment of breast cancer patients with tamoxifen [J] .World Journal of Clinical Oncology,2014,5(3):374-381.
- [25] Lei L,Wang X,Wu XD,et al.Association of CYP2D6*10 (c100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population [J] .American Journal of Translational Research,2016,8(8):3585-3592.
- [26] Irvin WJ,Walko CM,Weck KE,et al.Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study [J] .Journal of Clinical Oncology,2011,29(24):3232-3239.
- [27] Kiyotani K,Mushiroda T,Imamura CK,et al.Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients [J] .Breast Cancer Research and Treatment,2012,131(1):137-145.
- [28] Dezentjé VO,van Schaik RH,Vletter-Bogaartz JM,et al.CYP2D6 genotype in relation to tamoxifen efficacy in a dutch cohort of the tamoxifen/exemestane adjuvant multinational (TEAM) trial [J] .Breast Cancer Research and Treatment,2013,140(2):363-373.
- [29] Hertz DL,Kidwell KM,Hilsenbeck SG,et al.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen:results from a population-based study [J] .Breast Cancer Research and Treatment,2017,166(1):277-287.
- [30] Goetz MP,Suman VJ,Hoskin TL,et al.CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8 [J] .Clinical Cancer Research,2013,19(2):500-507.
- [31] Ramón y Cajal T,Altés A,Paré L,et al.Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment [J] .Breast Cancer Research and Treatment,2010,119(1):33-38.
- [32] Bijl MJ,van Schaik RH,Lammers LA,et al.The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users [J] .Breast Cancer Research and Treatment,2009,118(1):125-130.

备注/Memo: -

更新日期/Last Update: 1900-01-01